Masimo (MASI) Expected to Announce Quarterly Earnings on Tuesday

Masimo (NASDAQ:MASI) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect Masimo to post earnings of $1.24 per share and revenue of $367.79 million for the quarter.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $164.04 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market cap of $8.86 billion, a PE ratio of 113.13 and a beta of 1.28. The company has a 50-day simple moving average of $165.40 and a 200-day simple moving average of $165.90. Masimo has a 12 month low of $101.61 and a 12 month high of $194.88.

Insider Activity at Masimo

In other news, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

MASI has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Thursday, April 10th. Wells Fargo & Company increased their target price on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Piper Sandler upped their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.